inflammatory bowel disease
Although it has seemingly tried to do everything, everywhere, all at once with its immune sequencing technology, Adaptive has sharpened its focus.Â
The Seattle-based company recently completed a strategic reorganization around its two major business areas by cutting the workforce and appointing a new CFO.
The Seattle-based company recently published immune repertoire data showing the potential of T-cell receptor profiling in IBD diagnostics.
Adaptive Biotechnologies to Focus on Immune Medicine, Minimal Residual Disease Testing Businesses
Premium
The Seattle-based company said this week that its immune medicine and minimal residual disease testing business arms will drive the firm's future growth.
ProciseDx Enters Markets for Inflammation, Medication Monitoring With Five-Minute POC Instrument
Premium
The firm has developed an instrument that uses fingerstick blood or stool samples to enable quantitative results for the management of conditions caused by inflammation.